Accenture stock drops even after Wells Fargo upgrade as investors stay cautious on IT services

Accenture stock drops even after Wells Fargo upgrade as investors stay cautious on IT services

February 17, 2026

NEW YORK, Feb 17, 2026, 14:26 EST — Regular session

Accenture plc dropped 1.6% to $220.61 as of 2:11 p.m. ET, erasing earlier gains. A Wells Fargo upgrade didn’t do much to support the stock. Shares moved between $217.41 and $229.33, with volume hitting around 4.9 million.

Accenture’s status as a bellwether for corporate tech spending and outsourcing—particularly in consulting-centric segments—makes these shifts notable. When a bullish analyst call barely moves the stock, it’s a clue: investors are holding out for concrete results, not just improved analyst rhetoric.

Bookings, those new contract signings that could eventually boost revenue, are right in the thick of the debate. Bulls see signs the pipeline’s picking up. Bears, though, are still questioning if the timing and makeup of projects will play along.

Wells Fargo’s Jason Kupferberg raised his rating on Accenture to “Overweight” from “Equal Weight,” sticking to his $275 price target. Kupferberg highlighted two straight quarters of better bookings growth and argued fears over Accenture’s AI exposure are “overblown.” TipRanks

Zacks Equity Research bumped Accenture up to a Rank #2 (Buy) on Tuesday, pointing to higher earnings estimates as the key driver in its model. The group put the consensus EPS for fiscal 2026, which ends in August, at $13.87. That number’s moved up roughly 0.7% in the past three months, according to Zacks.

Accenture slipped, mirroring a weaker stretch for IT services, despite the broader market staying firm. The SPDR S&P 500 ETF edged up roughly 0.3%. IBM shed 1.3%, Cognizant was down 2.4%, Infosys gave up 0.6%, and EPAM Systems dropped 2.7%.

Accenture’s most recent guidance put second-quarter revenue between $17.35 billion and $18.0 billion, while the company left its full-year local currency revenue growth target steady at 2% to 5%.

The guidance sets up a possible upside if bookings keep rolling in and projects move ahead as planned. Still, there’s not much cushion if project mix tilts toward slower launches or if pricing pressure returns.

Another straightforward risk: if clients drag their feet on decisions and keep discretionary budgets tight, the upgrade cycle could lose momentum quickly. Then “second-half acceleration” turns elusive, and the stock might just keep feeling the weight.

Accenture’s fiscal Q2 earnings call lands March 19 at 8:00 a.m. EST. Bookings, margins, and the revenue outlook will be under the microscope for investors.

Marcin Frąckiewicz

Marcin Frąckiewicz is the CEO of TS2 Space and a longtime technology entrepreneur focused on telecommunications, satellite communications and digital innovation. A graduate of the Warsaw School of Economics (SGH), he writes about space technology, artificial intelligence and publicly traded technology companies. His analysis covers major market trends, emerging technologies and the businesses shaping the future of the global economy.

Stock Market Today

  • Telix Pharmaceuticals (ASX:TLX) and Predictive Discovery (ASX:PDI) Draw Attention on Insider Ownership, Growth
    July 27, 2026, 1:30 PM EDT. Investors are looking at companies with both strong insider ownership and visible growth paths as inflation and central banks shape the market. Telix Pharmaceuticals (ASX:TLX), with a market cap of A$5.0 billion, claims a spot in radiopharmaceuticals for cancer and has a US presence and late-stage clinical trials. Predictive Discovery (ASX:PDI), a gold explorer at A$3.1 billion, is developing West African projects but comes with financial and dilution risks highlighted by recent losses. Both names mix growth stories with insider backing, but their risk profiles vary, giving investors a range of growth-focused, insider-led picks for watchlists.